1. Home
  2. RDI vs LGVN Comparison

RDI vs LGVN Comparison

Compare RDI & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

N/A

Current Price

$1.25

Market Cap

23.4M

ML Signal

N/A

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.68

Market Cap

25.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
LGVN
Founded
1937
2014
Country
United States
United States
Employees
2005
N/A
Industry
Movies/Entertainment
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.4M
25.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RDI
LGVN
Price
$1.25
$0.68
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
15.1K
277.1K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
$16.25
N/A
Revenue Next Year
$4.04
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.48
52 Week High
$1.65
$1.80

Technical Indicators

Market Signals
Indicator
RDI
LGVN
Relative Strength Index (RSI) 46.94 39.72
Support Level $0.99 $0.62
Resistance Level $1.26 $0.68
Average True Range (ATR) 0.06 0.06
MACD -0.01 -0.01
Stochastic Oscillator 5.01 28.07

Price Performance

Historical Comparison
RDI
LGVN

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: